Dr Lalchandani Labs Ltd (DLCL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Dr Lalchandani Labs Ltd on NSE and BSE, with an AI summary of each filing.
The company due to ill health of the Chairman of the Company had filed the Application for extension of Annual General Meeting (AGM) for FY 2025-26, the ROC Delhi has considered and approved ....
Annual General Meeting · 18 Sept 2026, 1:57 am
Audited Financial Results for the quarter and year ended March 31, 2026
Outcome · 04 Jun 2026, 3:07 am
Dr Lalchandani Labs FY26 Results Weak; Auditor Flags Repayment Defaults, NPA Status Dr Lalchandani Labs reported a FY26 net profit of ₹6.35 lacs, down 85% YoY from ₹41.72 lacs, despite a one-time exceptional gain of ₹61.08 lacs from a loan settlement. Revenue from operations for FY26 fell 6% YoY to ₹418.58 lacs. The auditor issued a qualified opinion, highlighting the company's NPA status with lenders, defaults on loan repayments despite significant cash reserves, non-payment of statutory dues like PF and ESIC, and failure to provide for gratuity and leave encashment liabilities.
Audited Financial Results for the half year and year ended March 31, 2206
Financial Result · 04 Jun 2026, 2:57 am
Dr Lalchandani Labs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 213 (-8.3% YoY | +4.1% QoQ) ■ EBITDA: -18.6 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -8.7 (Profit to Loss YoY | Profit to Loss QoQ) ■ PAT: -13.2 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.15 (Profit to Loss YoY | Profit to Loss QoQ)
Intimation of Postponement and Rescheduling of Board Meeting scheduled to be held on Today May 30, 2026.
Others (Uncategorized) · 31 May 2026, 1:00 am
Dr Lalchandani Labs Postpones Board Meeting for FY26 Results Dr Lalchandani Labs (BSE: 541299) has postponed its board meeting originally scheduled for 30 May'26. The meeting was intended to approve financial results for the half-year and year ended 31 Mar'26. The delay is due to an ongoing internal review of financial and operational data. Management will complete this review before presenting the statements. The board meeting has been rescheduled to Wednesday, 03 Jun'26, to consider and approve the said financial results. This unexpected delay may attract scrutiny regarding internal financial controls.
We are pleased to inform that the Company has successfully opened a new strategic Centre at Dwarka New Delhi.
Others (Uncategorized) · 28 May 2026, 11:43 pm
Dr Lalchandani Labs Opens New Strategic Centre in Dwarka Dr Lalchandani Labs (BSE: 541299) announced on 28 May'26 the opening of a new strategic centre in Dwarka, New Delhi. The company expects the new facility to generate approximately Rs. 1 Crore in annual business. The expansion targets the large government employee population in the Dwarka and Palam areas, regions with historically limited business for the company. This move is part of its strategy to expand its footprint in high-potential markets and strengthen its presence in West Delhi, enhancing customer outreach and brand visibility.
Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve financial results of the ....
Intimation · 30 May 2026, 5:30 am
Dr Lalchandani Labs Board Meeting to Approve FY26 Results Dr Lalchandani Labs (BSE: 541299) has scheduled a Board of Directors meeting on Sat, 30 May'26. The agenda includes consideration and approval of the audited financial results for the half-year and full-year ended 31 Mar'26. In compliance with SEBI insider trading regulations, the trading window will remain closed until 48 hours after the results are declared.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 04 May 2026, 6:19 pm
Dr Lalchandani Labs States It Is Not a "Large Corporate" Under SEBI Rules Dr Lalchandani Labs announced on 04 May'26 that it does not qualify as a "Large Corporate" per SEBI's circular dated 26 Nov'18. The company's classification is based on its long-term borrowings being less than the threshold of Rs. 1000 crores as of 31 Mar'26. Consequently, the mandatory borrowing requirements through debt securities for the FY25-26 block period are not applicable to the company.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 7:20 pm
Dr Lalchandani Labs Not Classified as a Large Corporate by SEBI Dr Lalchandani Labs Limited filed a disclosure on 30-Apr'26 confirming it has not been identified as a Large Corporate (LC) as of 31-Mar'26. This classification is based on the framework outlined in SEBI's circular on fund raising via debt securities. Consequently, the company is not subject to the mandatory borrowing requirements applicable to LCs. The filing states that details regarding outstanding borrowings, credit ratings, and potential fines for shortfalls are not applicable.
Resignation of Mrs. Saniya Hussain from the position of Company Secretary and Compliance Officer
Change in Management · 22 Apr 2026, 10:05 pm
Dr Lalchandani Labs Company Secretary Saniya Hussain Resigns Dr Lalchandani Labs (Scrip: 541299) announced the resignation of Mrs. Saniya Hussain from her position as Company Secretary and Compliance Officer, effective 22 Apr'26. The resignation letter cited personal/professional reasons for her departure. The company confirmed there are no other material reasons for the change. This marks a key management personnel change for the company, requiring a search for a successor to fulfill critical compliance and secretarial functions as per SEBI regulations.
Reply to the clarification sought by exchange dated April 13, 2026
Others (Uncategorized) · 14 Apr 2026, 1:14 am
Dr Lalchandani Labs: No Undisclosed Information on Share Price Movement Dr Lalchandani Labs, in a response to the BSE dated 13 Apr'26, clarified the recent movement in its share price. The company confirmed there is no pending price-sensitive information or announcement that could have caused the significant price change. It stated the share price movement is completely market-driven. The company affirmed its commitment to complying with all disclosure requirements under applicable regulations.
The Exchange has sought clarification from Dr Lalchandani Labs Ltd on April 13, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 14 Apr 2026, 1:00 am
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anuraag Gambhir
Acquisition/ Disposal of Shares · 05 Mar 2026, 9:19 pm
Anuraag Gambhir Acquires 15.05% Stake in Dr. Lalchandani Labs Anuraag Gambhir acquired 13,00,000 equity shares of Dr. Lalchandani Labs Limited on 02 Mar'26 via a rights issue allotment. This transaction increased his holding from a negligible 2 shares to 13,00,002 shares, representing 15.05% of the post-acquisition voting capital. Following the allotment, the company's total equity share capital increased from Rs. 4,33,30,680 to Rs. 8,63,70,680. This substantial acquisition was disclosed under SEBI's SAST Regulations, 2011.
Approval of basis of allotment under Right issue
Others (Uncategorized) · 03 Mar 2026, 3:31 am
Dr Lalchandani Labs Allots 43.04 Lakh Shares in Rights Issue Dr Lalchandani Labs' board, on Mar 02, '26, approved the allotment of 43,04,000 fully paid-up equity shares at an issue price of ₹10 per share. This allotment concludes the rights issue that ran from Feb 04, '26 to Feb 27, '26, raising ₹430.40 lakhs. Consequently, the company's total number of equity shares has increased from 43,33,068 to 86,37,068, and the total paid-up share capital has doubled to ₹8,63,70,680. This action significantly expands the company's equity base.
Board meeting for approval of basis of allotment for right issue
Others (Uncategorized) · 03 Mar 2026, 3:29 am
Dr Lalchandani Labs Completes Rights Issue, Doubles Paid-Up Capital Dr Lalchandani Labs’ Board on Mar 02, '26, approved the allotment of 43,04,000 equity shares under its rights issue at an issue price of ₹10 per share. The issue, which opened on Feb 04, '26, and closed on Feb 27, '26, raised an aggregate amount of ₹4.30 crore. Following the allotment, the company's total number of equity shares has increased from 43,33,068 to 86,37,068, doubling its paid-up share capital from ₹4.33 crore to ₹8.64 crore.
We wish to inform you that the Board of Directors of the Company considered and approved the extension of closing date of the ongoing right issue. The issue has been extended to February ....
Outcome · 16 Feb 2026, 8:43 pm
Dr Lalchandani Labs Extends Rights Issue Timeline Dr Lalchandani Labs has extended its Rights Issue closing date to Friday, Feb 27, '26, from the original date of Feb 20, '26. The extension aims to facilitate better shareholder participation. Accordingly, the on-market renunciation of Rights Entitlements has also been extended to Tuesday, Feb 24, '26. The issue opened on Feb 04, '26. Key post-issue dates include allotment on Mar 02, '26, and listing on or about Mar 05, '26. Other terms of the issue remain unchanged.
This is in reference to the 'Outcome of the Meeting of Board of Directors' dated January 20, 2026, we wish to inform you that the Board of Directors of Dr Lalchandani Labs Limited, at its ....
Others (Uncategorized) · 16 Feb 2026, 7:42 pm
Dr Lalchandani Labs Extends Rights Issue Closing Date Dr Lalchandani Labs Ltd. has extended the closing date of its ongoing rights issue to Fri, Feb 27, '26, from the original date of Fri, Feb 20, '26. The extension aims to facilitate better shareholder participation. The issue opened on Wed, Feb 04, '26. Key subsequent dates include finalization of allotment by Mon, Mar 02, '26, and listing of new shares on or about Thu, Mar 05, '26. All other terms of the Letter of Offer dated Jan 20, '26 remain unchanged.
Newspaper publication as per stated regulation
Others (Uncategorized) · 31 Jan 2026, 5:52 pm
Dr Lalchandani Labs Announces Rights Issue Details Dr Lalchandani Labs announced its rights issue, scheduled to open on Jan 31, '26, and close on Feb 06, '26. The issue price is set at ₹10 per equity share, with a record date of Jan 27, '26. The company completed the dispatch of the letter of offer and application form on Jan 30, '26. Shareholders can apply through the ASBA process or by submitting plain paper applications. The last date for on-market renunciation of rights entitlements is Feb 03, '26.
Please find enclosed the soft copy of Letter of Offer dated January 20, 2026, for the Rights Issue of Dr Lalchandani Labs Limited. The Company is also submitting this Letter of Offer with ....
Rights Issue · 22 Jan 2026, 4:22 am
Dr Lalchandani Labs Announces ₹4.33 Crore Rights Issue at Par Dr Lalchandani Labs has announced a rights issue of up to 43,32,000 equity shares at a face value of ₹10 each, aggregating to ₹4.33 crore. The issue is priced at par (₹10/share) with a 1:1 entitlement ratio for eligible shareholders. The record date is set for 27 Jan'26. The issue will open on 04 Feb'26 and close on 20 Feb'26. Net proceeds of ₹4.11 crore are intended for working capital, adjustment of promoter's unsecured loans, and repayment of outstanding borrowings, aiming to strengthen the company's financial position.
ntimation of Record Date pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Others · 21 Jan 2026, 2:16 am
Dr Lalchandani Labs Announces Record Date for Rights Issue Dr Lalchandani Labs (BSE: 534920) has announced a record date for its upcoming rights issue of equity shares. The company has fixed Tuesday, 27 Jan '26, as the cut-off date to determine shareholder eligibility for receiving rights entitlements. This action is pursuant to Regulation 42 of SEBI's Listing Regulations. Further details on the rights issue, such as the ratio and price, have not yet been disclosed in this filing.
In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors ....
Others (Uncategorized) · 21 Jan 2026, 2:11 am
Dr Lalchandani Labs Approves ₹4.33 Crore Rights Issue Dr Lalchandani Labs' board approved a rights issue to raise ₹4.33 crore by issuing 43.32 lakh equity shares at ₹10 each. The entitlement ratio is set at 1 rights share for every 1 share held. The record date to determine shareholder eligibility is Jan 27, '26. The issue will open on Feb 04, '26 and close on Feb 20, '26. Post-issue, the company's paid-up equity shares will increase from 43.33 lakh to 86.65 lakh, assuming full subscription.
In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors ....
Outcome · 21 Jan 2026, 2:09 am
Dr Lalchandani Labs Announces 1:1 Rights Issue to Raise ₹4.33 Crore Dr Lalchandani Labs approved a rights issue to raise ₹4.33 crore by offering 43,32,000 equity shares at ₹10 each. The entitlement ratio is set at 1 rights share for every 1 share held. The record date to determine eligibility is 27 Jan'26. The issue will open on 04 Feb'26 and close on 20 Feb'26. Post-issue, the number of outstanding equity shares will increase from 43,33,068 to 86,65,068, assuming full subscription. This move will double the company's paid-up equity share capital.
In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors ....
Others (Uncategorized) · 20 Jan 2026, 11:56 pm
Dr Lalchandani Labs Announces ₹4.33 Crore Rights Issue Dr Lalchandani Labs board approved a rights issue to raise ₹4.33 Cr by issuing 43,32,000 equity shares at ₹10 each. The entitlement ratio is set at 1:1. The record date to determine shareholder eligibility is Jan 27, '26. The issue will open on Feb 04, '26, and close on Feb 20, '26. Post-issue, outstanding equity shares will increase to 86,65,068. The last date for on-market renunciation is Feb 17, '26, and for off-market is Feb 20, '26.
We are pleased to inform that the company has received the In-principle approval from BSE Limited for Rights issue of Equity Shares, the letter is enclosed
Rights Issue · 17 Jan 2026, 2:26 am
Dr Lalchandani Labs Receives In-Principle Nod for Rights Issue Dr Lalchandani Labs has received in-principle approval from BSE Limited for its proposed rights issue of equity shares. The approval, dated 16 Jan '26, allows the company to proceed with the issuance of fully paid-up equity shares to eligible shareholders on a rights basis. The number of shares and the issue price have not yet been disclosed. The listing is subject to the completion of all post-issue requirements and compliance with statutory and legal formalities as stipulated by the exchange.
This is with reference to our prior intimation dated December 16, 2025, wherein we had informed the Exchange about the meeting of the Board of Directors of Dr Lalchandani Labs Limited ('the ....
Outcome · 22 Dec 2025, 10:59 pm
Dr Lalchandani Labs Defers Board Meeting on Rights Issue Dr Lalchandani Labs Ltd. has deferred its board meeting originally scheduled for Dec 22, '25. The meeting was intended to approve key terms for a proposed Rights Issue, including the record date, issue price, and entitlement ratio. The postponement is due to the non-receipt of the required In-Principle Approval from the BSE. The company will reconvene to approve the Rights Issue details once the exchange approval is secured.
Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/12/2025 ,inter alia, to consider and approve fixation of the record ....
Intimation · 16 Dec 2025, 11:25 pm
Dr Lalchandani Labs Board to Finalize Terms for Rights Issue Dr Lalchandani Labs will hold a Board Meeting on 22 Dec'25 to finalize the terms for its previously approved rights issue. The Board had approved raising funds not exceeding ₹433.31 lakhs via a rights issue of equity shares with a face value of ₹10 each on 15 Dec'25. The upcoming meeting will determine key details including the record date, issue price, and the rights entitlement ratio. This action is crucial for the company's planned capital raise and will be closely watched by investors.